Sfmg LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

Sfmg LLC acquired a new stake in Zoetis Inc. (NYSE:ZTSFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,356 shares of the company’s stock, valued at approximately $268,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Bell Private Wealth Management LLC raised its holdings in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares in the last quarter. Evermay Wealth Management LLC raised its holdings in Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares in the last quarter. Worth Asset Management LLC acquired a new stake in Zoetis in the first quarter valued at approximately $26,000. Finally, Moisand Fitzgerald Tamayo LLC raised its holdings in Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after acquiring an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the transaction, the executive vice president now owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.12% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday. Stifel Nicolaus cut their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. The Goldman Sachs Group raised their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, Barclays raised their price objective on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $221.75.

View Our Latest Stock Report on ZTS

Zoetis Price Performance

Shares of NYSE ZTS opened at $151.94 on Thursday. Zoetis Inc. has a one year low of $148.48 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The company’s fifty day moving average is $177.35 and its two-hundred day moving average is $180.39. The firm has a market capitalization of $69.49 billion, a P/E ratio of 29.97, a PEG ratio of 2.34 and a beta of 0.85.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the firm earned $1.15 earnings per share. Zoetis’s quarterly revenue was up 8.5% on a year-over-year basis. Analysts forecast that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.14%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.